9 results about "Glomerular diseases" patented technology

The traditional Chinese medicine composition disclosed by the invention adopts a method of warming yang and relieving exterior syndrome to achieve the effects of freeing lung and inducing diuresis, tonifying spleen and warming kidney, and strengthening defensive qi and diminishing swelling, and is prepared to be used for treating the immune-related glomerular diseases, especially membranous nephropathy and minimal lesion nephropathy. The traditional Chinese medicine composition is a pure traditional Chinese medicine preparation, clinical observation and in-vivo and in-vitro basic tests show that the prescription can remarkably improve edema, massive proteinuria, hypoproteinemia and the like, meanwhile, compared with the prior art, the traditional Chinese medicine composition has a better effect on symptoms such as stomachache and diarrhea, has an anti-inflammatory effect and does not have obvious side effects in clinical application. The traditional Chinese medicine composition has an excellent effect on patients suffering from membranous nephropathy and minimal lesion nephropathy caused by syndrome differentiation of spleen-kidney yang deficiency, internal rheumatism and water-fluid overflowing.

Collapsing focal segmental glomerulosclerosis (collapsing FSGS), also known as collapsing glomerulopathy (CG), is the most aggressive variant of FSGS and is characterized by rapid progression to end-stage kidney disease (ESKD). The inventors used the telomerase-induced mouse model of CG (i-TERTci mice) to identify mechanisms to inhibit CG pathogenesis. They found that inactivation of WIP1 phosphatase, a p53 target acting in a negative feedback loop, blocks disease initiation in i-TERTci mice. They found that pharmacologic inhibition of WIP1 enzymatic activity in either telomerase mice with CG or in Tg26 mice promotes partial remission of proteinuria and ameliorates renal histopathologic features. Their findings suggest that targeting WIP1 may be an effective therapeutic strategy for patients with CG. Thus, the present invention relates to a method of preventing or treating glomerular disease (e.g. focal segmental glomerulosclerosis, in particular collapsing glomerulopathy) in a subject in need thereof, comprising the step of administering to said subject a Wild-type p53-induced phosphatase 1 (WIP1) inhibitor.

The present disclosure relates to a method. The method includes accessing a digitized pathology image stored in a memory. The digitized pathology image is from a glomerular disease patient. A plurality of peritubular capillary (PTC) features are extracted from the digitized pathology image. The plurality of PTC features include a plurality of PTC spatial architecture features and a plurality of PTC shape features. The plurality of PTC features are provided to a machine learning stage. The machine learning stage is configured to generate a medical prediction relating to glomerular disease based upon the plurality of PTC features.

The invention provides a glomerular anomaly recognition system and method based on Raman spectrum and artificial intelligence, and relates to the field of biosensing and artificial intelligence, and the method comprises the following steps: collecting and pretreating real-time Raman spectrum of glomerular related biomolecular components in a blood or urine sample; extracting a key spectrum peak and an intensity characteristic of the Raman spectrum; comparing the extracted key spectrum peak and the intensity characteristic thereof with the key spectrum peak and the intensity characteristic thereof of the normal glomerulus to obtain a difference characteristic; and constructing a glomerular anomaly identification model, and identifying the glomerular anomaly condition by taking the difference distinguishing features as input features of the glomerular anomaly identification model. According to the glomerular anomaly recognition system and method based on the Raman spectrum and the artificial intelligence, accuracy, real-time performance and noninvasive performance of glomerular disease diagnosis are achieved through spectrum collection hardware optimization, AI algorithm innovation, clinical tool integration and safety protocol deployment.

Disclosed are methods and compositions for detecting glomerular disease in dogs and effectively treating dogs with glomerular diseases such as amyloidosis, glomerulosclerosis, or immune complex-mediated glomerulonephritis. miRNAs associated with glomerular disease are also provided, as are kits, and methods of use.

This invention discloses a dynamic monitoring and analysis system for immune inflammation in patients with glomerular diseases, applicable to the field of medical testing and data analysis. The system includes a data acquisition module, a multi-omics detection module, a dynamic data analysis module, a visualization and reporting module, and an early warning module. The multi-omics detection module integrates the joint detection of immune inflammation-related proteins (such as CCL11 and CXCL9), metabolic markers (such as N-acetyl-L-leucine), and oxidative stress markers (such as RAC2). The dynamic data analysis module is built based on the XGBoost algorithm and calculates a "dynamic immune score" to quantitatively assess disease activity and predict trends. This invention overcomes the shortcomings of traditional single-marker methods, such as poor specificity and inability to dynamically monitor, achieving non-invasive, multi-dimensional, and real-time monitoring of the immune inflammatory status of glomerular diseases, providing decision support for precise clinical diagnosis and treatment.

The present invention relates to the development of therapeutic compound for the treatment of glomerular diseases. Specifically, present invention relates to use of compound of formula (Ia) or its pharmaceutically acceptable salt or combination thereof or pharmaceutical composition thereof for the treatment of glomerular diseases.

Compositions and methods for decreasing a level of expression or activity of BMP binding endothelial regulator (BMPER) are provided. Also provided are antisense oligonucleotides (ASOs) that target BMPER.